Anti-MDA5 dermatomyositis with rapidly progressive ILD
Amyopathic DM, fulminant lung disease · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Anti-MDA5 antibody-positive dermatomyositis is frequently clinically amyopathic but carries a high risk of rapidly progressive interstitial lung disease with very high mortality. Cutaneous ulceration, palmar papules and minimal muscle weakness with acute hypoxaemic respiratory failure are characteristic.
Red flags
- Rapidly rising oxygen requirement
- Ferritin >1500-3000 micrograms/L and rising
- Extensive/worsening ground-glass or consolidation on HRCT
- Cutaneous ulceration (poor prognostic sign)
- Pneumomediastinum
Assessment
Differential diagnosis
- Antisynthetase syndrome
- Acute interstitial pneumonia / ARDS
- Severe infective pneumonia (incl. opportunistic)
- Other CTD-associated ILD
- Diffuse alveolar haemorrhage
- Hypersensitivity pneumonitis
Investigations
- Myositis antibody panel including anti-MDA5 (anti-CADM-140)
- Serum ferritin (very high predicts poor prognosis)
- High-resolution CT chest and serial lung function / transfer factor
- ABG and continuous oxygen saturation monitoring
- CK (often normal/mildly raised), LDH, KL-6 where available
- Infection screen including PJP and respiratory viral PCR
Management
- Recognise the high-risk phenotype: DM skin signs, little weakness, rising ferritin, falling oxygenation
- Admit to HDU/ICU early and provide oxygen / ventilatory support
- Exclude and empirically cover infection (including PJP)
- Start aggressive triple immunosuppression without delay - delay worsens survival
- Combine high-dose corticosteroid, a calcineurin inhibitor and cyclophosphamide/rituximab
- Consider plasma exchange or JAK inhibitor in refractory rapidly progressive disease per specialist advice
- Monitor serial ferritin, oxygenation and HRCT as prognostic markers
- Discuss early with ILD/transplant and ICU teams given high mortality
Drugs & doses
Methylprednisolone — 1 g IV OD for 3 days then prednisolone 1 mg/kg/day
Tacrolimus — 0.075 mg/kg/day PO, adjusted to trough 5-10 micrograms/L
Cyclophosphamide — 500-1000 mg/m2 IV monthly (dose-adjusted)
Tofacitinib — 5 mg PO BD (emerging option in refractory anti-MDA5 RP-ILD)
Co-trimoxazole — 480-960 mg PO OD for PJP prophylaxis with intensive immunosuppression
Disposition
Admit to ICU/HDU; immediate triple immunosuppression with combined rheumatology, respiratory and intensive care input.
Complications & pitfalls
- Fatal rapidly progressive respiratory failure
- Pneumomediastinum / pneumothorax
- Superimposed opportunistic infection
- Multi-organ failure
- Treatment-related toxicity
Exam pearls
- Among the highest-mortality rheumatological lung presentations - aggressive early combination therapy improves survival
- Ferritin level tracks disease activity and prognosis
- Muscle enzymes may be normal (clinically amyopathic) - do not be falsely reassured
- Spontaneous pneumomediastinum is a recognised ominous feature
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.